| scholarly article | Q13442814 |
| P50 | author | Patricia Ganz | Q57838486 |
| Laurel A Habel | Q82880626 | ||
| Bette J. Caan | Q87148470 | ||
| P2093 | author name string | Steven W Cole | |
| Erin K Weltzien | |||
| P2860 | cites work | Aspirin intake and survival after breast cancer | Q24604280 |
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| NSAIDs and breast cancer recurrence in a prospective cohort study | Q28221965 | ||
| Rethinking screening for breast cancer and prostate cancer | Q28261959 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Weight, weight gain, and survival after breast cancer diagnosis | Q28305155 | ||
| Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. | Q50569886 | ||
| Solving the overdiagnosis dilemma. | Q50696285 | ||
| Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. | Q51545574 | ||
| Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. | Q52994367 | ||
| Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials | Q56658918 | ||
| Risk of first-time hospitalization for angioedema among users of ACE inhibitors and angiotensin receptor antagonists | Q57300748 | ||
| Host Factors and Cancer Outcome | Q60595416 | ||
| Physical Activity and Survival After Breast Cancer Diagnosis | Q29040191 | ||
| Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials | Q33803829 | ||
| Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis | Q33815723 | ||
| Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer | Q34078823 | ||
| Overdiagnosis in cancer | Q34111655 | ||
| Weight, physical activity, diet, and prognosis in breast and gynecologic cancers | Q34131967 | ||
| Host factors and cancer progression: biobehavioral signaling pathways and interventions | Q34131970 | ||
| The sympathetic nervous system induces a metastatic switch in primary breast cancer | Q34134468 | ||
| Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort | Q34134850 | ||
| Molecular basis of metastasis. | Q34304177 | ||
| Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: the life after cancer epidemiology study | Q34334908 | ||
| Pathways for bradykinin formation and inflammatory disease | Q34528274 | ||
| Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. | Q34662845 | ||
| Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? | Q34749837 | ||
| Nutrition and survival after the diagnosis of breast cancer: a review of the evidence | Q34767869 | ||
| The influence of bio-behavioural factors on tumour biology: pathways and mechanisms | Q35135129 | ||
| Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival | Q35640094 | ||
| Beta-adrenergic signaling, a novel target for cancer therapy? | Q35640106 | ||
| Molecular insights into prostate cancer progression: the missing link of tumor microenvironment | Q35980774 | ||
| Angiotensin receptors: a new role in cancer? | Q36215159 | ||
| Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors | Q36426544 | ||
| Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma | Q37276048 | ||
| Angiotensin inhibition and malignancies: a review. | Q37429773 | ||
| Adrenoceptors: non conventional target for breast cancer? | Q37481897 | ||
| Tumor-stromal cell interactions and opportunities for therapeutic intervention | Q37773720 | ||
| Tumor-host interactions: a far-reaching relationship | Q37774174 | ||
| Body size and breast cancer prognosis: a critical review of the evidence. | Q37790609 | ||
| The renin-angiotensin system and cancer: old dog, new tricks. | Q37802186 | ||
| Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents | Q37803154 | ||
| Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma | Q40252227 | ||
| Metabolic profile, physical activity, and mortality in breast cancer patients | Q43250781 | ||
| Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark | Q44608163 | ||
| Insulin breast cancer connection: confirmatory data set the stage for better care | Q44667568 | ||
| Is it time to test metformin in breast cancer clinical trials? | Q46110594 | ||
| Life After Cancer Epidemiology (LACE) Study: a cohort of early stage breast cancer survivors (United States). | Q46236225 | ||
| Weight gain in early-stage breast cancer: where do we go from here? | Q47212114 | ||
| A cohort study of antihypertensive medication use and breast cancer among Danish women. | Q50543915 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 549-556 | |
| P577 | publication date | 2011-04-11 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort | |
| P478 | volume | 129 |
| Q35024342 | Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment |
| Q37960818 | Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. |
| Q86732555 | Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer |
| Q50535266 | Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. |
| Q36932703 | Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use |
| Q36092918 | Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint |
| Q35949297 | Beta-adrenergic blocking drugs in breast cancer: a perspective review |
| Q27014939 | Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies |
| Q35466477 | Can analyses of electronic patient records be independently and externally validated? Study 2--the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study |
| Q39171512 | Cardio-oncology Related to Heart Failure: Common Risk Factors Between Cancer and Cardiovascular Disease |
| Q50045986 | Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. |
| Q34040240 | Challenges associated with peripheral arterial disease in women |
| Q38226775 | Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality: a review of the literature |
| Q37017213 | Comorbidities and breast cancer survival: a report from the Shanghai Breast Cancer Survival Study. |
| Q44103169 | Comorbidity burden and guideline-concordant care for breast cancer |
| Q52598231 | Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study. |
| Q37705334 | Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer |
| Q47372688 | Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database |
| Q37445916 | Control of bone remodeling by the peripheral sympathetic nervous system |
| Q30235047 | Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: Evidence from a meta-analysis including 55 studies |
| Q35093193 | Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts |
| Q47586430 | Effect of antihypertensive drugs on breast cancer risk in female hypertensive patients: Evidence from observational studies |
| Q38370090 | Effects of complementary and integrative medicine on cancer survivorship |
| Q58077030 | Emergence, Development, and Future of Cardio-Oncology in China |
| Q93066935 | Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial |
| Q99418687 | Exercise and immunometabolic regulation in cancer |
| Q41902409 | Expression of β-adrenergic receptors in pediatric malignant brain tumors. |
| Q33739341 | Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality |
| Q36587690 | Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC. |
| Q38293740 | Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β-adrenergic system. |
| Q36159232 | Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation |
| Q35756617 | Long-Term Use of Antihypertensive Agents and Risk of Breast Cancer: A Population-Based Case-Control Study |
| Q33555154 | Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches |
| Q35132413 | Meta-analysis of the effects of beta blocker on survival time in cancer patients |
| Q89304755 | Pharmacologic Management of Cancer Therapeutics-Induced Cardiomyopathy in Adult Cancer Survivors |
| Q39187514 | Potentiation of Paclitaxel-Induced Pain Syndrome in Mice by Angiotensin I Converting Enzyme Inhibition and Involvement of Kinins. |
| Q28074453 | Repurposing of approved cardiovascular drugs |
| Q32174211 | Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease |
| Q48745127 | Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study |
| Q92838614 | Risk of second breast cancer events with chronic opioid use in breast cancer survivors |
| Q36709155 | Shared Risk Factors in Cardiovascular Disease and Cancer |
| Q41472414 | Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study |
| Q99572232 | Stress reduction strategies in breast cancer: review of pharmacologic and non-pharmacologic based strategies |
| Q47289333 | Sympathectomy reduces tumor weight and affects expression of tumor-related genes in melanoma tissue in the mouse |
| Q47863448 | Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. |
| Q92521553 | The Behavioral Medicine Research Council: Its origins, mission, and methods |
| Q57168537 | The effects of beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patients |
| Q92064761 | The evolution of professional societies in behavioral medicine |
| Q36570909 | The β2-adrenoceptor activates a positive cAMP-calcium feedforward loop to drive breast cancer cell invasion. |
| Q38734603 | Up-Regulation of Angiotensin-Converting Enzyme (ACE) Enhances Cell Proliferation and Predicts Poor Prognosis in Laryngeal Cancer |
| Q37121758 | Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes |
| Q38625054 | Use of antihypertensive medications and risk of adverse breast cancer outcomes in a SEER-Medicare population |
| Q38750495 | Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis |
| Q36916770 | Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study |
| Q38068208 | β-adrenergic-blocking drugs and melanoma: current state of the art. |
| Q36443830 | β-blockers: a novel class of antitumor agents |
Search more.